Fideuram Intesa Sanpaolo Private Banking S.P.A. Has $2.89 Million Stock Position in Progyny, Inc. $PGNY

Fideuram Intesa Sanpaolo Private Banking S.P.A. raised its holdings in shares of Progyny, Inc. (NASDAQ:PGNY) by 141.9% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 170,076 shares of the company’s stock after acquiring an additional 99,764 shares during the quarter. Fideuram Intesa Sanpaolo Private Banking S.P.A.’s holdings in Progyny were worth $2,888,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. California State Teachers Retirement System raised its holdings in Progyny by 0.7% in the 2nd quarter. California State Teachers Retirement System now owns 70,421 shares of the company’s stock valued at $1,549,000 after acquiring an additional 457 shares in the last quarter. Teza Capital Management LLC grew its holdings in shares of Progyny by 5.4% during the 2nd quarter. Teza Capital Management LLC now owns 10,068 shares of the company’s stock worth $221,000 after purchasing an additional 516 shares in the last quarter. Aristides Capital LLC grew its holdings in shares of Progyny by 4.6% during the 3rd quarter. Aristides Capital LLC now owns 11,938 shares of the company’s stock worth $257,000 after purchasing an additional 528 shares in the last quarter. Leibman Financial Services Inc. grew its holdings in shares of Progyny by 1.2% during the 4th quarter. Leibman Financial Services Inc. now owns 46,435 shares of the company’s stock worth $1,192,000 after purchasing an additional 528 shares in the last quarter. Finally, Oxford Asset Management LLP increased its position in shares of Progyny by 4.3% in the second quarter. Oxford Asset Management LLP now owns 12,918 shares of the company’s stock worth $284,000 after purchasing an additional 531 shares during the period. 94.93% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Progyny

In other news, insider Geoffrey Clapp sold 1,530 shares of the stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $25.58, for a total value of $39,137.40. Following the completion of the transaction, the insider directly owned 59,117 shares in the company, valued at approximately $1,512,212.86. This represents a 2.52% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Kevin K. Gordon sold 5,500 shares of the firm’s stock in a transaction on Wednesday, May 27th. The shares were sold at an average price of $24.99, for a total value of $137,445.00. Following the sale, the director directly owned 9,318 shares in the company, valued at approximately $232,856.82. This trade represents a 37.12% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 36,916 shares of company stock valued at $939,875. 9.90% of the stock is owned by company insiders.

Progyny Stock Performance

Shares of Progyny stock opened at $30.22 on Friday. The firm’s 50 day moving average is $24.58 and its 200 day moving average is $22.53. The firm has a market capitalization of $2.37 billion, a PE ratio of 39.25, a price-to-earnings-growth ratio of 2.67 and a beta of 1.01. Progyny, Inc. has a 1 year low of $16.10 and a 1 year high of $30.33.

Progyny (NASDAQ:PGNY) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.50 EPS for the quarter, beating the consensus estimate of $0.26 by $0.24. Progyny had a net margin of 5.23% and a return on equity of 13.34%. The business had revenue of $328.50 million during the quarter, compared to the consensus estimate of $326.46 million. During the same quarter in the prior year, the firm earned $0.17 EPS. The firm’s revenue was down 26.4% compared to the same quarter last year. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. As a group, research analysts anticipate that Progyny, Inc. will post 1.07 earnings per share for the current year.

Progyny announced that its board has approved a stock repurchase program on Tuesday, May 26th that allows the company to buyback $200.00 million in outstanding shares. This buyback authorization allows the company to purchase up to 10.3% of its stock through open market purchases. Stock buyback programs are often an indication that the company’s board of directors believes its shares are undervalued.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the stock. Canaccord Genuity Group raised shares of Progyny from a “hold” rating to a “buy” rating and upped their price objective for the stock from $19.00 to $30.00 in a research report on Tuesday, May 19th. Bank of America raised their target price on shares of Progyny from $29.00 to $31.00 and gave the company a “buy” rating in a report on Tuesday, June 2nd. Wall Street Zen upgraded shares of Progyny from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 27th. Jefferies Financial Group reaffirmed a “buy” rating and set a $30.00 price target on shares of Progyny in a report on Friday, March 6th. Finally, Weiss Ratings upgraded shares of Progyny from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, June 26th. Eleven equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $29.92.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.